We are live on ! Find out more
INMB icon

INmune Bio

82 hedge funds and large institutions have $6.09M invested in INmune Bio in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

45% more call options, than puts

Call options by funds: $55K | Put options by funds: $38K

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

11% more funds holding

Funds holding: 7482 (+8)

1.1% more ownership

Funds ownership: 19.12%20.23% (+1.1%)

23% less capital invested

Capital invested by funds: $7.93M → $6.09M (-$1.85M)

Holders
82
Holders Change
+8
Holders Change %
+10.81%
% of All Funds
1.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
25
Reduced
21
Closed
9
Calls
$55K
Puts
$38K
Net Calls
+$17K
Net Calls Change
-$34K

INMB Hedge Fund Activity: Q1 2026 in Review

82 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2026, worth a combined $6.09M — down 23% from $7.93M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new INMB positions and 9 closed out — a net gain of 9 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $356K. The largest seller was Dauntless Investment Group, cutting an estimated $173K.

  • 82 institutional investors held INmune Bio (INMB) as of Q1 2026, up from 74 in Q4 2025.
  • Funds reported $6.09M of INmune Bio stock for Q1 2026, down 23% quarter-over-quarter.
  • 18 funds opened new INmune Bio positions in Q1 2026 and 9 closed out, a net change of +9 holders.
  • The largest INmune Bio buyer in Q1 2026 was AQR Capital Management, an estimated $356K added.
  • The largest INmune Bio seller in Q1 2026 was Dauntless Investment Group, an estimated $173K sold.

Based on aggregated 13F filings for Q1 2026.